Follow up of Nasolacrimal Intubation in Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
For patients with chronic epiphora, Dacryocystorhinostomy is currently the gold standard treatment, with a success rate of 80-90% according to literature. Another available treatment, which is far less used, in nasolacrimal intubation, using a silicone tube.
In our study, we would like to find the efficacy of nasolacrimal duct intubation, which was performed in our medical center on a few hundred patients with mild epiphora.
Study hypothesis: nasolacrimal intubation in adults, with a clinically mild epiphora, is close in it's efficacy to the Dacryocystorhinostomy procedure.
| Condition | Intervention |
|---|---|
|
Lacrimal Apparatus Diseases Dacryocystitis |
Device: Silicone tube |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Long Term Follow up of Nasolacrimal Intubation in Adults With Mild Epiphora |
- Patient being completely free of tearing. [ Time Frame: 1 year. ] [ Designated as safety issue: No ]
- Following nasolacrimal intubation, did the patient need a Dacryocystorhinostomy surgery. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Enrollment: | 180 |
| Study Start Date: | January 2000 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Primary
All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
|
Device: Silicone tube
Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
|
Detailed Description:
Under normal conditions, the amount of tears excreted from lacrimal glands to the eye is equal to the amount drained through the tear duct. Epiphora in adults usually involves a blockage of the lacrimal sac or the nasolacrimal duct. Epiphora causes tearing in patients, which can be treated sympthomatically in a conservative way (antibiotic treatment, probing of the tear duct, pressure irrigation of the tear duct) or therapeutic in an invasive way. The invasive treatment includes one of the following:
- Dacryocystorhinostomy - surgery for reconstructing an alternative path for tear drainage.
- Nasolacrimal intubation - inserting a silicone tube through the tear duct. The tube is usually removed after 3-6 months.
Currently, there are only a few reports regarding the efficacy of nasolacrimal intubation, all with a small number of research subjects. Also, these reports have stratified the patients according to the location of the tear duct blockage, and didn't take into account the severity of the blockage (ie the severity of symptoms) prior to performing the intubation.
In our research, we would like to find the efficacy of nasolacrimal intubation which was performed in our medical center on a few hundred patients with mild epiphora, and to compare in with the efficacy of the Dacryocystorhinostomy - which is 80-90% according to literature.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patient who underwent nasolacrimal intubation in Maccabi Healthcare, due to mild epiphora, during the years 2000-2007.
Inclusion Criteria:
- Clinical diagnosis of mild epiphora.
- Underwent nasolacrimal intubation during 01/2000 - 12/2007.
Exclusion Criteria:
- Purulent excretions from nasolacrimal duct on day of admission or intubation.
- Nasolacrimal intubation in the past.
- Dacryocystorhinostomy in the past.
Contacts and Locations| Israel | |
| Maccabi Healthcare Eye Clinic | |
| Tel Aviv, Israel | |
| Study Director: | Arie Nemet, MD | Shaare Zedek Medical Center, Maccabi Healthcare |
| Study Chair: | Arie Nemet, MD | Shaare Zedek Medical Center, Maccabi Healthcare |
| Principal Investigator: | Arie Nemet, MD | Shaare Zedek Medical Center, Maccabi Healthcare |
More Information
Publications:
| Responsible Party: | Arie Nemet, MD, Shaare Zedek Medical center, Maccabi Healthcare Services |
| ClinicalTrials.gov Identifier: | NCT00706251 History of Changes |
| Other Study ID Numbers: | LTFNIAME |
| Study First Received: | June 26, 2008 |
| Last Updated: | June 26, 2008 |
| Health Authority: | Israel: Ethics Commission |
Additional relevant MeSH terms:
|
Dacryocystitis Lacrimal Apparatus Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 16, 2013